Novogen (KZIA) Competitors $8.09 +0.06 (+0.75%) Closing price 09/4/2025 03:59 PM EasternExtended Trading$8.01 -0.08 (-1.05%) As of 09/4/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KZIA vs. THAR, RVPH, MAAQ, ITRM, RNTX, KZR, PMN, ASBP, CASI, and CLSDShould you be buying Novogen stock or one of its competitors? The main competitors of Novogen include Tharimmune (THAR), Reviva Pharmaceuticals (RVPH), Mana Capital Acquisition (MAAQ), Iterum Therapeutics (ITRM), Rein Therapeutics (RNTX), Kezar Life Sciences (KZR), Promis Neurosciences (PMN), Aspire Biopharma (ASBP), CASI Pharmaceuticals (CASI), and Clearside Biomedical (CLSD). These companies are all part of the "pharmaceutical products" industry. Novogen vs. Its Competitors Tharimmune Reviva Pharmaceuticals Mana Capital Acquisition Iterum Therapeutics Rein Therapeutics Kezar Life Sciences Promis Neurosciences Aspire Biopharma CASI Pharmaceuticals Clearside Biomedical Novogen (NASDAQ:KZIA) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation. Is KZIA or THAR more profitable? Novogen's return on equity of 0.00% beat Tharimmune's return on equity.Company Net Margins Return on Equity Return on Assets NovogenN/A N/A N/A Tharimmune N/A -1,239.20%-365.06% Which has more risk and volatility, KZIA or THAR? Novogen has a beta of 2.19, suggesting that its stock price is 119% more volatile than the S&P 500. Comparatively, Tharimmune has a beta of 1.56, suggesting that its stock price is 56% more volatile than the S&P 500. Which has stronger earnings & valuation, KZIA or THAR? Tharimmune has lower revenue, but higher earnings than Novogen. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNovogen$1.51M5.41-$17.56MN/AN/ATharimmuneN/AN/A-$12.20M-$6.10-0.65 Do insiders & institutionals believe in KZIA or THAR? 30.9% of Novogen shares are owned by institutional investors. Comparatively, 1.2% of Tharimmune shares are owned by institutional investors. 1.0% of Novogen shares are owned by company insiders. Comparatively, 10.0% of Tharimmune shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts rate KZIA or THAR? Novogen presently has a consensus price target of $14.00, indicating a potential upside of 73.05%. Tharimmune has a consensus price target of $17.00, indicating a potential upside of 326.07%. Given Tharimmune's higher probable upside, analysts plainly believe Tharimmune is more favorable than Novogen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novogen 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Tharimmune 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Does the media favor KZIA or THAR? In the previous week, Tharimmune had 2 more articles in the media than Novogen. MarketBeat recorded 2 mentions for Tharimmune and 0 mentions for Novogen. Tharimmune's average media sentiment score of 0.46 beat Novogen's score of 0.00 indicating that Tharimmune is being referred to more favorably in the news media. Company Overall Sentiment Novogen Neutral Tharimmune Neutral SummaryNovogen and Tharimmune tied by winning 5 of the 10 factors compared between the two stocks. Get Novogen News Delivered to You Automatically Sign up to receive the latest news and ratings for KZIA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KZIA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KZIA vs. The Competition Export to ExcelMetricNovogenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.09M$3.13B$5.75B$9.85BDividend YieldN/A2.28%6.67%4.51%P/E RatioN/A20.8975.9926.43Price / Sales5.41458.96546.94119.09Price / CashN/A44.5237.0558.92Price / Book-0.829.9310.916.06Net Income-$17.56M-$53.38M$3.29B$266.28M7 Day Performance0.61%0.63%0.19%-0.32%1 Month Performance-6.80%6.31%6.27%3.44%1 Year Performance-60.54%11.63%51.55%23.11% Novogen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KZIANovogenN/A$8.09+0.7%$14.00+73.1%-57.7%$8.09M$1.51M0.0012THARTharimmune2.7758 of 5 stars$5.54-7.0%$17.00+207.1%+34.3%$31.73MN/A-0.912Short Interest ↑RVPHReviva Pharmaceuticals2.3779 of 5 stars$0.46+1.3%$5.20+1,040.4%-64.3%$31.01MN/A-0.705MAAQMana Capital AcquisitionN/A$3.81+0.5%N/A+1,078.8%$30.96MN/A0.001Gap DownITRMIterum Therapeutics3.2254 of 5 stars$0.67-0.6%$9.00+1,237.3%-40.4%$30.28MN/A-0.8010News CoveragePositive NewsShort Interest ↓RNTXRein TherapeuticsN/A$1.26-9.4%N/AN/A$29.37MN/A-0.479News CoverageKZRKezar Life Sciences2.7797 of 5 stars$3.89-1.4%$9.00+131.1%-32.4%$28.50M$7M-0.4060PMNPromis Neurosciences2.8023 of 5 stars$0.54+0.8%$4.33+696.6%-67.4%$28.19MN/A-2.595News CoverageASBPAspire BiopharmaN/A$0.57-1.1%N/AN/A$28.17MN/A0.00N/ANews CoverageCASICASI Pharmaceuticals3.6813 of 5 stars$2.29-1.0%$4.00+75.0%-65.9%$28.12M$28.54M-0.79180Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionGap DownCLSDClearside Biomedical2.3623 of 5 stars$0.35-3.7%$4.20+1,086.4%-63.5%$27.79M$1.66M-0.9630Gap Down Related Companies and Tools Related Companies THAR Alternatives RVPH Alternatives MAAQ Alternatives ITRM Alternatives RNTX Alternatives KZR Alternatives PMN Alternatives ASBP Alternatives CASI Alternatives CLSD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KZIA) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novogen Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Novogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KZIA Stock Alerts